deltatrials
Completed PHASE2 NCT00114218

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

Sponsor: Gynecologic Oncology Group

Conditions Recurrent Uterine Corpus Sarcoma Uterine Carcinosarcoma
Interventions Docetaxel Gemcitabine Hydrochloride
Updated 10 times since 2017 Last updated: Dec 17, 2018 Started: Mar 31, 2005 Primary completion: Jul 31, 2010

Listed as NCT00114218, this PHASE2 trial focuses on Recurrent Uterine Corpus Sarcoma and Uterine Carcinosarcoma and remains completed. Sponsored by Gynecologic Oncology Group, it has been updated 10 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Feb 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

  5. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 5 earlier versions

  1. Dec 2018 — Feb 2019 [monthly]

    Completed PHASE2

  2. Nov 2018 — Dec 2018 [monthly]

    Completed PHASE2

  3. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gynecologic Oncology Group
  • National Cancer Institute (NCI)
Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Philadelphia, United States